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Abstract After hepatitis B virus (HBV) infection, HBV
DNA persists in minute amounts in hepatocyte nuclei even
in individuals with “resolved” infection. Viral replication and
development of liver disease depend on the balance between
viral mechanisms promoting persistence and host immune
control. Patients with active or inactive disease or resolved
HBV infection are at risk for reactivation with immunosup-
pressive therapy use. HBVreactivation varies from a clinically
asymptomatic condition to one associated with acute liver
failure and death. We review recent studies on HBV reactiva-
tion during immunomodulatory therapies for oncologic, gas-
troenterological, rheumatic, and dermatologic disorders. Risk
calculation should be determined through HBV screening and
assessment of immunosuppressive therapy potency. We also
discuss monitoring for reactivation, prophylactic antiviral
therapy, and treatment of reactivation. Prophylactic antiviral
treatment is needed for all HBsAg carriers and selected
patients who have anti-HBc without HBsAg and is critical
for preventing viral reactivation and improving outcomes.
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Introduction
Over half of the world’s population has been exposed to
hepatitis B virus (HBV), and it is generally estimated that
there are 350 million chronic carriers worldwide [1, 2]. HBV
infection is usually denoted by the detection of hepatitis B
surface antigen (HBsAg) in serum, while clearance of HBsAg
is generally considered consistent with resolution of active
infection. The vast majority of people with serological recov-
ery from HBV infection (HBsAg-negative, antibody to hepa-
titis B core antigen (anti-HBc)-positive, with or without hep-
atitis B surface antibody [anti-HBs]) have undetectable HBV
DNA in serum, yet HBV DNA persists in minute amounts in
the nuclei of hepatocytes [3]. In individuals who do not clear
the infection and progress to develop chronic HBV infection
(HBsAg-positive and anti-HBc-positive), serum HBV DNA
levels vary greatly from undetectable (<20 international units
[IU]/ml) to >1,000,000,000 (>9 log10) IU/ml [4]. This broad
range of serum HBV DNA reflects a balance between viral
replication fitness and host control defenses, namely innate
and adaptive immune system activation [5, 6].
Immunosuppression can alter this balance enough to induce
the clinical entity of HBV reactivation (HBVr). Reactivation is
best characterized as a virologic event in which there is a sudden
increase in viral replication due to loss of immune control.
Frequently, although not always, there is concomitant evidence
of inflammatory liver disease, with an elevation in serum ami-
notransferase levels and, in severe cases, elevation of bilirubin
level. While reactivation can also occur spontaneously as part of
the natural history of chronic HBV infection, the most common
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clinical setting involves the use of chemotherapeutic or immu-
nosuppressive drug therapy [7]. Reactivation during cancer
chemotherapy has been well recognized but has also been
reported with most immunosuppressive agents. Such agents
are now often used in hematologic, gastrointestinal, rheumatic,
dermatologic, and pulmonary diseases, as well as in transplan-
tation (solid organ and stem cell). Inhibitors of interleukins 17
and 23 are currently under development and are likely to further
increase rheumatology and dermatology patient exposure [8].
Thus, drug-induced HBVr will become a more common entity
facing a broader range of medical specialists.
While the particular immune effector systems that are
inhibited vary between drugs, all inhibit adaptive immunity
to HBV which renders the chronically infected HBV patient
with HBsAg(+) status or occult infection susceptible to reac-
tivation [9]. It is not well understood why some patients
demonstrate reactivation during immunosuppressive drug
therapy whereas others with similar virologic and biochemical
features fail to do so; nor is it understood what determines
such a broad spectrum of clinical severity, from asymptomatic
with minimal if any ALT increase to severe or fulminant.
However, insights have been gained from recent case series
that identify patient and viral factors that increase the likeli-
hood of reactivation [10, 11]. Experience with newer immu-
nosuppressive therapies has provided a better means of iden-
tifying agents that present a risk for reactivation [12, 13].
Mechanisms of Reactivation
Once infected with HBV, patients harbor covalently closed
circular (ccc) HBV DNA and pre-genomic viral transcripts in
hepatocyte nuclei forever [14]. Even with serologic resolution
of infection (with loss of HBsAg, undetectable serum HBV
DNA, and appearance of anti-HBs) ccc HBV DNA can re-
main in hepatocytes and other cells for the life of the patient
[15]. Rehermann et al. reported HBV cccDNA to be present in
hepatocytes and circulating peripheral mononuclear cells fol-
lowing clinically resolved infection [16]. Even patients with
isolated anti-HBc status (presence of anti-HBc without
HBsAg or anti-HBs) who have “cleared” infection in the
remote past also harbor minute quantities of HBV cccDNA
in a small minority of hepatocytes and remain at risk of HBVr.
During a period of viral latency, HBV replication in the liver
or in peripheral mononuclear cells is controlled through effec-
tor arms of adaptive immunity, including HBV-specific CD4+
helper T cells, HBV-specific CD8+ cytotoxic T cells, appro-
priately primed B cells which can serve as antigen presenting
cells, and cytokines such as interferon gamma and tumor
necrosis factor (TNF) alpha [17]. When host adaptive immu-
nity is compromised by immunosuppressive therapy directed
against either T cells or B cells, there is resultant loss of
immune control allowing for increased HBV replication.
Moreover, biochemical flares sometimes occur once cytotoxic
T cell-mediated responses are restored after completion of
therapy (immune reconstitution) [18].
Non-immune pathways have also been implicated in
HBVr. In HBV-infected transgenic mice, irradiation of the
liver plus interleukin-6 therapy caused in vitro HBV replica-
tion through STAT3 signaling [19]. HBVr can also occur
directly with steroid usage via st imulation of a
glucocorticoid-responsive element in the HBV genome which
leads to upregulation of HBV gene expression [20]. Viral
factors that have been associated with sudden increases in
HBV replication and immunologic flares during HBeAg-
negative hepatitis B include the HBV precore mutation
G1896A and the basal core promoter mutation T1762/
A1764 [21, 22].
Clinical Manifestations
Reactivation of HBV has a heterogeneous clinical presenta-
tion, ranging from asymptomatic and subclinical to severe
acute liver failure and death. HBVr during cancer chemother-
apy is often conceptualized to occur in phases. During the first
phase, increasing serum HBV DNA levels occur. This can be
accompanied by the reappearance of HBsAg [23]. Amino-
transferases may or may not be elevated and the patient is
often asymptomatic. The second phase begins days to weeks
later when elevation in aminotransferase levels due to cellular
immunity rebound are observed in response to further increase
in viral replication and even higher serum HBV DNA. Clin-
ical symptoms commonly encountered in hepatitis (fatigue,
malaise, and jaundice) may become evident. During this
phase, progression to acute liver failure and death may occur.
With cancer chemotherapy, this second phase is thought to be
explained by the immune reconstitution that occurs during the
interval between courses of treatment; although this hepatitis
flare frequently occurs after the first few cycles of chemother-
apy, it can occur at any time [24, 25]. In severe HBVr with
progressive hepatocyte injury and liver failure indicators of
poor prognosis include jaundice, encephalopathy, ascites, el-
evated bilirubin levels or increased INR and renal failure as a
late phase event. Liver transplantation can be considered;
however, many patients are disqualified on the basis of their
underlying disease (e.g., malignancy). In many patients, there
is a third phase in which hepatic injury from HBVr either
resolves spontaneously or following discontinuation of immu-
nosuppressive therapy or initiation of antiviral therapy [26].
Nomenclature
There is great need for standardized nomenclature and defini-
tion of HBVr. Varied definitions have been used to define the
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virologic event (de novo appearance of HBVDNA in a patient
previously known to be negative; tenfold increase in HBV
DNA over previous levels; or even HBV DNA >20,000 IU at
the time of a sudden elevation of the aminotransferases).
Many reports indicate that an increase in serum aminotrans-
ferases should be part of the definition; however, abnormali-
ties of ALT or AST may not be observed [27]. In 2013, a
consensus conference, the American Association for the
Study of Liver Diseases (AASLD) Emerging Trends Confer-
ence, was convened by AASLD on HBVr [28]. An important
part of the agenda was proposing standardized nomenclature
to facilitate more accurate reporting and collaboration among
practitioners from varied specialties. It was proposed that
reactivation of HBV replication be defined as an increase in
HBV replication (≥2 log increase from baseline level) or de
novo appearance of HBV DNA in a patient in whom previous
testing found it to be non-detectable. Reactivation of past
hepatitis B can be further defined as reappearance of HBsAg
(in those who were previously documented to be negative) or
appearance of HBV DNA alone in the absence of HBsAg.
Irrespective of the presenting virologic and serologic features,
reactivation can vary from an asymptomatic condition to one
that is life threatening with acute liver failure and possible
need for transplantation.
Risk Factors for Reactivation
Information from case series of chronically infected HBV
patients has identified a number of risk factors for reactivation.
These can be characterized as patient factors, viral factors,
underlying diseases, type of transplantation as well as the type
and intensity of immunosuppression [29–31].
Patient Factors
Male sex and younger patient age have been associated with
HBVr. In a recent study of 78 HBsAg-positive patients with
various cancers receiving chemotherapeutic regimens, ap-
proximately 30 % of males had reactivation compared with
10% of females [32]. It is unclear if gender-related differences
in adaptive HBV-related immunity exist or if the increased
risk with male sex relates to gender-based differences in
incidence of diseases necessitating immunosuppressive
therapy.
Viral Factors
HBV replication status (prior to initiation of immunosuppres-
sive therapy) has been identified as a risk factor. Chronically
infected patients with HBsAg-positivity have a higher risk of
reactivation compared with anti-HBc-positive patients who
are HBsAg-negative. In HBsAg-positive patients, levels of
HBV DNA prior to therapy are associated with risk of reac-
tivation, with those having relatively high levels (>2000 IU) at
higher risk compared with those having lower levels of HBV
DNA [33]. The association between HBV DNA levels and
risk of reactivation is likely also true for anti-HBc positive
patients [34]. In patients who are HBsAg-negative and anti-
HBc-positive, anti-HBs level is thought to be a factor as well,
with those having undetectable anti-HBs level at the onset of
immunosuppressive therapy and those who have loss of anti-
HBs during immunosuppressive therapy at increased risk for
reactivation [35, 36]. The association between the virologic
and serologic status of the host and reactivation risk is likely to
be explained by a spectrum of immunologic control over
HBV, with HBeAg-positive, highly viremic HBsAg carriers
at one extreme and non-viremic, anti-HBc/anti-HBs-positive
patients at the other. Seen this way, it can be anticipated that
the HBsAg carrier would be more likely to reactivate with
mild to moderate immunosuppressive drug therapy (e.g., cer-
tain TNF-alpha inhibitors) whereas those positive for anti-
HBc generally can be anticipated to have a much lower risk
unless very intensive immunosuppressive treatments are giv-
en such as Rituximab combined with Cyclophosphamide,
doxorubicin hydrochloride/Hydroxydaunomycin, vincristine
sulfate/Oncovin, and Prednisone (R-CHOP) for lymphoma or
leukemia.
Underlying Disease
The highest incidence of HBVr has been observed in patients
receiving chemotherapy for hematologic malignancies, partic-
ularly lymphomas treated with R-CHOP. Whether lymphoma
per se is associated with increased risk for HBVr is unknown.
Both HBVand HCVare known to be chronic viruses leading
to persistent B-cell activation and potential lymphomagenesis.
Evidence exists to support direct infection of B cells and
activation of signaling favoring tumorigenesis as well [37,
38]. This frequent association may be related to a higher
prevalence of HBV infection among patients with lymphoma
compared with controls [39] or may be a function of the
intense immunosuppressive regimen used, particularly in reg-
imens containing rituximab (Rituxan, Genentech, South San
Francisco, CA) [40••]. Case series of those receiving chemo-
therapy for lymphoma have shown that reactivation often
occurs after the second or third course of chemotherapy but
can occur at any time [41•, 42].
HBVr has also been recorded in patients undergoing che-
motherapy for solid tumors. Of the solid tumors, breast cancer
is most commonly associated with HBVr, and studies estimate
the rate of reactivation in HBsAg-positive patients with breast
cancer to be 25–40% [43, 44]. The high incidence of HBVr in
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patients with breast cancer has been attributed to the concom-
itant use of anthracyclines and corticosteroids. Both drugs
have been shown to increase HBV DNA transcription. It has
been shown in vitro that anthracyclines may promote tran-
scription through increased HBV secretion from hepatoblasts
[45] and steroids are known to increase viral transcription
through a steroid responsive element in the viral genome
[20]. HBVr has also been reported in patients treated for colon,
lung, and head and neck cancers, albeit at an overall lower
incidence (10-30 %) compared with breast [46, 47].
Immunosuppression Intensity
Intensity of immunosuppression has often been implicated as
a risk factor for HBVr [48]. When used in combination with
other immunosuppressive agents for treatment of lymphoma,
corticosteroids have been shown to increase the risk of reac-
tivation. In one report, 49 HBsAg-positive patients with non-
Hodgkin lymphoma were randomly assigned to receive che-
motherapy with or without prednisolone. Reactivation oc-
curred in 72 % of those who received prednisolone compared
with only 38 % of those who did not [49]. Studies have also
compared identical chemotherapy regimens for lymphoma
with and without rituximab. In one study of 46 HBsAg-
negative, anti-HBc-positive patients with lymphoma, 24 %
of patients treated with R-CHOP had HBVr compared with
none of those treated with only CHOP [50]. Evidence from
these and other studies seem to support either an additive or
synergistic effect of multiple immunosuppressive agents on
risk of HBVr [51]. Unfortunately, this means that complex
chemotherapy regimens often provide the best cancer re-
sponses but also a greater risk of HBV reactivation.
Immunosuppressive Agents
Various immunosuppressive agents, targeting diverse effec-
tors of the immune response, are used in oncologic, gastroin-
testinal, rheumatologic, and dermatologic diseases. Depend-
ing upon dose, combination, and patient risk factors, their use
can lead to HBVr.
Corticosteroids
Prednisone is a mainstay in some chemotherapeutic regi-
mens and an important agent for inducing remission in
inflammatory bowel disease. HBVr might partially be
explained by glucocorticoid-associated suppression of T
cell immune control. It is not known whether there is a
threshold dose or duration of corticosteroid use above
which the risk of HBVr increases but 2-4 weeks of low-
dose therapy such as is used in asthma is not thought to
present substantial risk. Reactivation has been reported in
patients receiving corticosteroids alone for varying indica-
tions [52, 53], and appears to be at least additive when
given in combination with other immunosuppressants.
Anti-Metabolites
Anti-metabolic agents interfering with nucleic acid syn-
thesis are often used in the treatment of inflammatory
bowel disease and rheumatoid arthritis (RA). Isolated
cases of HBVr have been reported in association with
methotrexate and azathioprine [54]. In addition, a case
of acute liver failure after withdrawal of chronic meth-
otrexate use for RA has been reported [55]. However,
these agents are considered as very low risk for HBV
when used as monotherapy.
Tumor Necrosis Factor-Alpha (TNF-α) Antagonists
Tumor necrosis factor-alpha (TNF-α) is a crucial pro-
inflammatory and immunoregulatory cytokine in the path-
ogenesis of various inflammatory conditions. A number of
anti-TNF-α agents are approved to treat conditions includ-
ing RA, ulcerative colitis, Crohn’s disease, and psoriasis.
TNF-α is also a critical cytokine in the coordination of
innate and adaptive immune defense against HBV infec-
tion [56]. Blockade of TNF-alpha signaling can lead to
increased HBV replication and reactivation. In a large
retrospective analysis of 89 HBsAg-positive and 168
HBsAg-negative, anti-HBc positive patients treated with
an anti-TNF agent, 35 HBsAg-positive patients (39 %)
experienced HBVr, among whom five developed associat-
ed liver failure with death resulting in four [57]. Among
the 168 HBsAg-negative, anti-HBc-positive patients, nine
(5 %) experienced HBVr, with one case of fatal acute
liver failure. Reactivation risk was higher with infliximab
compared to other anti-TNF agents, and with concomitant
use of other immunosuppressive drugs. In another investi-
gation of 122 patients with HBV infection treated with
anti-TNF agents, HBVr occurred in 15 (12.3 %), with
etanercept implicated in ten cases and infliximab in two
[10]. The U.S. Food and Drug Administration has issued a
warning regarding HBVr with use of infliximab [58].
While these warnings represent an important first step,
further investigation with regard to agent/indication and
dose-specific risk is needed and should be collected in
prospective, registered fashion to avoid case selection/
reporting bias.
Prospectively performed studies have reported variable
rates of activation with TNF-α use. In a small study, investi-
gators followed 21 HBsAg-negative, anti-HBc-positive RA
patients on TNF-α inhibitors and found no reactivation over
2 years [59]. In another study of 67 HBsAg-negative, anti-
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HBc-positive RA patients on therapy with an anti-TNF-α
agent (23 infliximab, 23 etanercept, 19 adalimumab), there
were no significant elevations of serum HBV DNA or appear-
ance of HBsAg during mean follow up of approximately
4 years [60].
Monoclonal Antibodies
Monoclonal antibodies, used to treat a wide variety of medical
conditions [61], interfere with ligand binding cell surface
receptors on either B or T cells, conferring immunomodulato-
ry effects. Recent experience with regimens containing ritux-
imab, a monoclonal antibody against the protein CD20 found
on the surface of B cells, has demonstrated that when used in
the treatment of malignancies in HBsAg-negative, anti-HBc-
positive patients, there was an approximately six times higher
odds ratio of HBVr compared to identical regimens without
rituximab [12, 62]. A preliminary analysis of the post-
marketing data from the FDA Adverse Event Reporting Sys-
tem found 109 cases of fatal HBV-related liver failure associ-
ated with rituximab or the anti-CD20 monoclonal antibody
ofatumumab (Arzerra, GlaxoSmithKline, Research Triangle
Park, NC); in more than half, screening was either inadequate
(testing for HBsAg but not anti-HBc) or had not been done
[63]. In September 2013, these findings prompted the FDA to
add HBVr to the existing BoxedWarning of the Rituxan label,
and to create a new Boxed Warning for the Arzerra label. In
the Warnings and Precautions section of the labels for both
drugs it is now recommended that before starting treat-
ment all patients be screened by measuring HBsAg and
anti-HBc; that when screening identifies patients at risk of
HBVr, a hepatitis expert be consulted regarding monitor-
ing and use of HBV antiviral therapy; that patients with
evidence of prior HBV infection be monitored for clinical
and laboratory signs of HBVr during therapy and for
several months thereafter since reactivation has occurred
up to 12 months after therapy completion with these
drugs; that in patients who develop HBVr while on ther-
apy, the drugs be immediately discontinued and appropri-
ate treatment for HBV be started; and that any chemother-
apy the patient is receiving be discontinued until the HBV
infection is controlled or resolved [64•]. HBVr has also
been reported in association with ibritumomab tiuxetan
(Zevalin) [65], a CD20-directed radiotherapeutic antibody
approved for treatment of B-cell non-Hodgkin lymphoma,
and with alemtuzumab (Campath) [66], a monoclonal an-
tibody directed against CD52 (expressed on B cells and T
cells, natural killer cells, and macrophages) which is
approved for refractory chronic lymphocytic leukemia
[67]; although there are no current label warnings relat-
ed to reactivation with these two drugs, physicians
should be aware of the possibility.
Systemic Chemotherapy
As discussed previously, HBVr has been studied most exten-
sively in patients receiving treatment for lymphoma. In an
early Asian study, 100 patients (27 HBsAg-positive; 51
HBsAg-negative/positive for anti-HBc and/or positive for
anti-HBs; 22 negative for all three) had HBV DNA levels
checked at baseline and prospectively followed [68]. HBVr-
related liver failure occurred in 7 %, 2 %, and 0 % of patients,
respectively. In another prospective study of 244 HBsAg-
negative patients who received chemotherapy for lymphoma,
eight developed reactivation (seven exposed to rituximab
regimen), of whom three progressed to liver failure, one of
whom died [69]. Combination regimens that contain
anthracyclines, docetaxel or epirubicin have been linked to
HBVr and death [43, 44]. HBVr has also been recognized with
treatment regimens used for lung, colon, and liver malignan-
cies [46, 70, 71].
Transarterial Chemoembolization (TACE)
Transarterial chemoembolization (TACE), in which chemo-
therapeutic agents are administered into a branch of the he-
patic artery, is used in treating hepatocellular carcinoma
(HCC). TACE is widely used for “downstaging” tumors prior
to liver transplantation [72, 73]. Reactivation of HBV replica-
tion has been reported in patients who have received TACE
[74, 75]. In instances where supraselective arterial injection
cannot be successfully accomplished or when there is inad-
vertent administration of the oncologic drug through arterio-
venous shunts, systemic exposure has been shown to occur,
partially accounting for the surprisingly high rate of reactiva-
tion in some case series [76••]. In a randomized controlled
study of HBsAg-positive patients with HCC who received
TACE with or without antiviral prophylaxis, HBVr was sub-




A critical issue in the prevention of HBVr is the identification
of those with HBV infection prior to initiation of immunosup-
pression. It estimated that in the U.S. less than one-third of
patients with chronic HBV are aware of their status [77]. No
validated screening tools have been routinely adopted into
clinical practice; and studies suggest screening for HBV is
greatly underutilized [78, 31]. Further complicating the issue
is the lack of uniformity among major societies and their
practice guidelines with regards to screening [79–82, 30,
83]. The development of appropriate screening tools and
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cost-effectiveness analysis studies are needed to determine the
utility of universal vs. at risk screening before the use of
immunosuppressive drug therapy.
Antiviral Therapy (Prophylactic, Preventive, and Therapeutic)
Prophylactic antiviral therapy (therapy initiated prior to or
concurrently with immunosuppressive therapy before an in-
crease in viral replication or biochemical evidence of disease)
has been demonstrated to greatly reduce although not complete-
ly eliminate HBVr and its sequelae. Antiviral therapy initiated
as soon as HBVDNA and low level ALT increase are observed
has also been suggested as a strategy in controlling HBVr. Five
oral nucleos(t)ide analogue drugs are available for HBV treat-
ment: lamivudine, adefovir, entecavir, telbivudine, and
tenofovir [84]. Only lamivudine and entecavir have so far been
studied as sole agents for either prophylaxis against or treatment
of reactivation. In a review of 14 studies that comparedHBsAg-
positive cancer patients on chemotherapy given lamivudine as
prophylaxis compared to patients not given prophylaxis, there
was a much lower pooled incidence of reactivation in those on
lamivudine (4 % vs 37 %) and fewer HBV-related deaths (2 %
vs 7 %), with no patients on lamivudine developing HBV-
associated liver failure compared to 13 % of those not given
prophylaxis [85]. However, resistance and hepatitis flares have
been reported in patients receiving preventive lamivudine dur-
ing immunosuppressive therapy [86]. Entecavir and tenofovir
are newer agents with potent antiviral activity; studies in im-
munocompetent patients with chronic hepatitis B have shown
minimal resistance in treatment-naïve patients receiving
entecavir and none with tenofovir [87, 88]. Entecavir as mono-
therapy has been shown to induce durable HBVDNA suppres-
sion in lymphoma patients treated with rituximab [40••, 89].
In two recent comparison studies, there has been a substan-
tially reduced rate of HBVr in chemotherapy-treated lymphoma
patients given entecavir prophylaxis (0 % [90] to 6.3 % [40••])
compared to those given lamivudine prophylaxis (12 % [90] to
39.3 % [40••]), as well as, in one study, markedly lower rates of
hepatitis (6 % versus 27 %) and chemotherapy interruptions
(6 % versus 20 %) [90]. In another recent study, among
rituximab-treated lymphoma patients who received prophylac-
tic entecavir (beginning prior to chemotherapy and continuing
until three months after chemotherapy completion; n=41) only
one patient (2.4 %) experienced HBVr compared to seven
patients (17.9 %) in the group chosen to receive only therapeu-
tic ETVat the time of HBVr (n=39) [91•]. In light of these and
other studies, entecavir appears to be a favored agent for HBVr
prophylaxis or therapy [92, 93], in large part because with long-
Fig. 1 Proposed algorithm for HBV reactivation treatment and monitor-
ing. Patients may be categorized into low, medium, or high risk dependent
upon baseline characteristics and proposed agents. In medium and high
risk populations serologic screening with HBsAg, anti-HBc, and Anti-
Hbs should be performed. Serologic screening should be performed in
those at low risk with unexplained abnormal aminotransferases † -In a
patient found to be anti-HBs positive and anti-HBc negative on initial
screen in a moderate risk setting, consider providing a dose of HBV
vaccine (40 µg) as intermediate gesture and then stop
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term use there may be resistance-associated failures of
lamivudine. While studies with tenofovir have not yet been
reported in this clinical situation, it is anticipated that its use
would be as effective for prophylaxis as entecavir. While pro-
phylactic antiviral therapy clearly appears to substantially lower
the risk of HBVr and can be applied in outpatient settings [94],
the cost effectiveness of this approach is dependent upon the
clinical population it is applied to and agent specific risk of
reactivation. For example, while a strong case can be made for
prophylactic therapy in HBsAg-positive patients treated with
rituximab, this approach would almost certainly not be cost
effective in patients who have isolated anti-HBc and are placed
on a single agent (for example, azathioprine) with limited
immunosuppressive potency (Fig. 1).
Therapy Cessation
While data supports the use of prophylactic therapy as well as
the use of the newer nucleos(t)ide analogues compared with
lamivudine, less is known about when therapy can be safely
withdrawn. In one study of 80 HBsAg-negative, anti-HBc-
positive patients with lymphoma randomly assigned to entecavir
prophylaxis or no prophylaxis (control), patients in the control
group developed reactivation as late as 17 months after the start
of rituximab, or approximately 11 months after the cessation of
rituximab therapy [95]. High levels of serum HBV DNA (≥4
log10 copies/ml) before chemotherapy predicted HBVr after
withdrawal of prophylactic antiviral therapy. Some experts feel
that antiviral treatment should generally be continued for six
months after immunosuppressive drug therapy is discontinued
and for 12 months when rituximab is used or whenever HBV
DNA above 2000 IU or 10,000 copies/mL is observed at
baseline [96]. Alternatively, while more challenging, case-by-
case decisions may need to be made with consideration of both
the potency and therapeutic half-life of the agent being used as
well as serologic and virologic status of the patient; for example,
the presence of sustainable high titer anti-HBs (>100 IU) on
immunosuppressive treatment requiring shorter term prophylax-
is and the presence of higher levels of HBV DNA at baseline
requiring longer periods of treatment/prophylaxis.
Conclusions
Reactivation represents a loss of immune control in those chron-
ically infected with or previously exposed to HBV. This loss of
control is often caused by immunosuppressive therapies through
various direct and indirect mechanisms. Immunosuppressive
therapy has revolutionized the treatment of many disorders.
New cytokine inhibitors such as anti-IL-17 [97] and anti-IL-23
[98] are being tested in a variety of clinical settings. As the use of
immunosuppressive agents increases, so too will the incidence
of HBVr and associated complications. Of critical importance is
screening at-risk populations for the presence of infection or
previous exposure. Multidisciplinary, randomized controlled
studies are needed to formulate a framework for risk stratifica-
tion based on patient and viral factors as well as disease indica-
tion and immunosuppressive agent.
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